Tradjenta
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Tradjenta (linagliptin; Boehringer Ingelheim/Eli Lilly) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut. Inhibition of DPP-IV augments the amount of active GLP-1, which in turn triggers increased insulin secretion from the pancreas in a glucose-dependent manner and suppresses the release of glucagon, resulting in lowered blood glucose levels.
The franchise product Jentadueto ([linagliptin + metformin]; Boehringer Ingelheim/Eli Lilly) addresses the fact that Tradjenta is generally used as a second- or third-line treatment option as an add-on to metformin.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Tradjenta : Diabetes type 2
LIST OF FIGURES
9 Figure 1: Tradjenta brand franchise for type 2 diabetes – SWOT analysis
10 Figure 2: Datamonitor Healthcare drug assessment of Tradjenta
11 Figure 3: Datamonitor Healthcare drug assessment scorecard for Tradjenta compared to Januvia
13 Figure 4: Tradjenta sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
15 Figure 5: Jentadueto sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
17 Figure 6: Glyxambi sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
4 Table 1: Tradjenta franchise products
5 Table 2: Tradjenta drug profile
5 Table 3: Jentadueto drug profile
6 Table 4: Overview of pivotal trial data for Tradjenta franchise in diabetes
14 Table 5: Tradjenta sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
16 Table 6: Jentadueto sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
18 Table 7: Glyxambi sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Onglyza 
Sign up to the